FDA Approves Exkivity (mobocertinib) for EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer (NSCLC)

[unable to retrieve full-text content]OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE) September 15, 2021 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved Exkivity… Drugs.com – New Drug Approvals

Your Diet Could Cut Your Odds for Severe COVID-19

Of course, Merino said, people with healthy diets may be different in many ways from those with less-healthful eating habits. So his team accounted for factors like age, race, exercise habits, smoking, body weight and whether people lived in low- or high-income neighborhoods. Obesity, for example, is a risk factor for severe COVID-19. And body… Read More »